Medi-Exametazim (Exametazime)

Medi-Exametazim is used in nuclear medicine to visualize sites of infection and inflammation through leukocyte labeling.

• Infection detection: enables visualization of bacterial infection sites using radiolabeled white blood cells.
• Osteomyelitis imaging: assists in locating bone infection and assessing treatment response.
• Fever of unknown origin: helps identify occult infectious foci when conventional tests are inconclusive.
• Inflammatory disease imaging: highlights active inflammatory lesions in conditions such as vasculitis or sarcoidosis.

• Exametazime penetrates leukocyte membranes and binds intracellular components, allowing the cells to be labeled with a technetium‑99m radionuclide. After intravenous administration, the labeled leukocytes migrate to areas of active infection or inflammation, where they emit gamma radiation detectable by SPECT imaging, thereby localizing pathological sites.

Adverse reactions may occur following intravenous administration of Exametazime‑labeled leukocytes.

Common Side Effects

• Nausea: mild, transient feeling of stomach upset.
• Headache: occasional mild to moderate intensity.
• Injection site pain: brief discomfort at the infusion site.
• Flushing: transient warmth or redness of the skin.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe hypotension: marked drop in blood pressure that may cause dizziness or fainting.
• Pulmonary embolism: rare clot formation in the lungs associated with radiolabeled cell aggregates.

Use of Medi-Exametazim requires careful assessment of patient-specific factors and handling requirements.

• Pregnancy: safety not established; avoid unless benefits outweigh potential risks.
• Breastfeeding: unknown excretion in milk; consider discontinuation of nursing.
• Renal impairment: monitor as altered clearance may affect image quality.
• Concurrent immunosuppressive therapy: may reduce leukocyte labeling efficiency.
• Known hypersensitivity to radiopharmaceutical components: assess risk before administration.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Exametazime may interact with other agents that affect leukocyte function or radiation exposure.

Major Interactions (Avoid)

• Concurrent radiolabeled leukocyte agents: may cause overlapping radiation dose.
• High‑dose corticosteroids: can suppress leukocyte labeling and reduce imaging sensitivity.
• Chemotherapeutic drugs causing leukopenia: diminish available leukocytes for labeling.

Moderate Interactions (Monitor Closely)

• Anticoagulants: may alter vascular imaging interpretation.
• Beta‑blockers: could mask cardiovascular side effects of the radiotracer.